Cargando…
An Integrative Approach to Dissect the Drug Resistance Mechanism of the H172Y Mutation of SARS-CoV-2 Main Protease
Nirmatrelvir is an orally available inhibitor of SARS-CoV-2 main protease (Mpro) and the main ingredient of PAXLOVID, a drug approved by FDA for high-risk COVID-19 patients. Recently, a rare natural mutation, H172Y, was found to significantly reduce nirmatrelvir’s inhibitory activity. As the COVID-1...
Autores principales: | Clayton, Joseph, de Oliveira, Vinicius Martins, Ibraham, Mohamed Fouad, Sun, Xinyuanyuan, Mahinthichaichan, Paween, Shen, Mingzhe, Hilgenfeld, Rolf, Shen, Jana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387124/ https://www.ncbi.nlm.nih.gov/pubmed/35982652 http://dx.doi.org/10.1101/2022.07.31.502215 |
Ejemplares similares
-
H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS-CoV-2 main protease through a nonnative hydrogen bond
por: de Oliveira, Vinicius Martins, et al.
Publicado: (2022) -
From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease †
por: Göhl, Matthias, et al.
Publicado: (2022) -
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
por: Zhang, Linlin, et al.
Publicado: (2020) -
How μ-Opioid Receptor Recognizes Fentanyl
por: Vo, Quynh N., et al.
Publicado: (2020) -
Polyelectrolyte in Electric Field: Disparate Conformational
Behavior along an Aminopolysaccharide Chain
por: Mahinthichaichan, Paween, et al.
Publicado: (2020)